Madrigal Pharmaceuticals, Inc. MDGL Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -27.7%+106pp | -31.3%+245pp | -41.5%+672pp | -60.1%+3,563pp | -134%— | |
| Net margin | -27.3%+96.1pp | -30.1%+229pp | -39%+636pp | -54.7%+3,432pp | -123.4%— | |
| EBITDA margin | -27.5%+106pp | -31.2%+245pp | -41.3%+671pp | -59.8%+3,558pp | -133.5%— | |
| Returns | ||||||
| Return on equity | -49.3%+0.8pp | -42.5%+37.9pp | -41.2%+88.5pp | -36.3%+70.0pp | -50.2%+38.6pp | |
| Return on assets | -27.8%+9.8pp | -25%+30.3pp | -23.7%+55.4pp | -26.7%+46.1pp | -37.7%+25.1pp | |
| Return on invested capital | -46.7%+37.3pp | -39.6%+44.0pp | -44.8%+99.4pp | -54.9%+115pp | -84%+102pp | |
| Efficiency | ||||||
| Asset turnover | 1×+0.7× | 0.8×+0.6× | 0.6×+0.5× | 0.5×+0.5× | 0.3×— | |
| Liquidity | ||||||
| Current ratio | 3.5×-2.4× | 4×-2.1× | 3.4×-2.5× | 5.1×-3.6× | 5.9×-3.5× | |
| Quick ratio | 3.2×-2.4× | 3.8×-2.1× | 3.3×-2.7× | 4.8×-3.9× | 5.6×-3.8× | |
| Cash ratio | 0.7×-0.4× | 0.7×0.0× | 0.8×-0.6× | 1×-3.0× | 1.1×-4.3× | |
| Leverage | ||||||
| Debt-to-equity | 0.7×+0.5× | 0.6×+0.4× | 0.6×+0.4× | 0.2×0.0× | 0.2×0.0× | |
| Debt-to-assets | 0.3×+0.2× | 0.3×+0.2× | 0.3×+0.2× | 0.1×0.0× | 0.1×0.0× | |
| Interest coverage | -11.7×+18.4× | -13.5×+20.5× | -17.6×+18.6× | -22.5×+12.9× | -30.1×+1.9× | |
| Per Share | ||||||
| Book value per share | $18.72-26.0% | $21.21-24.3% | $21.95-38.6% | $24.65-38.4% | $25.30-40.5% | |
| Valuation | ||||||
| Market capitalization | $12.01B+64.2% | $13.23B+96.5% | $10.22B+122% | $6.33B+6.0% | $7.31B+32.8% | |
| Enterprise value | $12.15B+67.5% | $13.37B+98.2% | $10.3B+129% | $6.27B+12.0% | $7.26B+44.7% | |
| Price / sales | 10.6×-12.4× | 13.8×-23.6× | 13.8×-46.2× | 12.3×-396× | 23×— | |
| Price / book | 22.1×+11.8× | 21.9×+13.0× | 16.3×+10.4× | 9.1×+2.1× | 10.3×+3.8× | |
| EV / sales | 10.7×-12.1× | 13.9×-23.5× | 13.9×-44.7× | 12.2×-371× | 22.9×— | |
| Earnings yield | -2.6%+2.8pp | -2.2%+4.7pp | -2.8%+8.4pp | -4.5%+4.1pp | -5.4%+2.7pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Madrigal Pharmaceuticals, Inc.'s profit margins?
- Madrigal Pharmaceuticals, Inc. (MDGL) runs a 96.5% gross margin and a -27.7% operating margin, with a -27.3% net margin.
- Where do Madrigal Pharmaceuticals, Inc.'s ratios come from?
- Every ratio is computed from Madrigal Pharmaceuticals, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
